FOXO TECHNOLOGIES INC. CEO SEAMUS LAGAN PROVIDES YEAR-END REVIEW TO SHAREHOLDERS
WEST PALM BEACH, FL, Dec. 15, 2025 (GLOBE NEWSWIRE) — FOXO Technologies Inc. (OTC: FOXO) (the “Company”), announces Chief Executive Officer Seamus Lagan has provided the following Year-End Review to…
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for…
Fondazione Telethon and Orphan Therapeutics Accelerator Sign Memorandum of Understanding to Pioneer Non-Profit Commercial Access Model for Ultra-Rare Disease Gene Therapy in the US
Collaboration Aims to Establish Sustainable Access to a Newly Approved Therapy Targeting a Rare Immunodeficiency, Filling Urgent Gap Left by For-Profit Efforts , /PRNewswire/ — Orphan Therapeutics Accelerator (OTXL), a…
Sentynl Therapeutics Announces FDA Acceptance of CUTX-101 NDA Resubmission
The investigational copper histidinate candidate receives new PDUFA Target Action Date of January 14, 2026 , /PRNewswire/ — Sentynl Therapeutics, Inc. (“Sentynl”), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences,…
MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
CARMEL, Ind., Dec. 15, 2025 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the…
NeuroSigma Completes $1 Million Investment into High-Volume Manufacturing Line for Second Generation Monarch eTNS® Device
Armstrong Asia of Singapore selected as NeuroSigma’s manufacturing partner Investment led by Checkmate Capital as part of strategic partnership with Armstrong Asia First commercial units to be delivered in March…
Seismic Therapeutic to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026
WATERTOWN, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) — Seismic Therapeutic, Inc., the machine learning immunology company, today announced that Jo Viney, Ph.D., Founder, President and Chief Executive Officer, will present…
Vor Bio Announces $150 Million Private Placement
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities…
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
New PDUFA Target Action Date of January 14, 2026 set by FDA MIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium…
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research and development in multiple immunology…